Amoxicillin
- Generic Name
- Amoxicillin
- Brand Names
- Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500
- Drug Type
- Small Molecule
- Chemical Formula
- C16H19N3O5S
- CAS Number
- 26787-78-0
- Unique Ingredient Identifier
- 9EM05410Q9
- Background
Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.
Amoxicillin was granted FDA approval on 18 January 1974.
- Indication
Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of Helicobacter pylori (H. pylori) infection.
Amoxicillin is used in combination with vonoprazan and clarithromycin as co-packaged triple therapy or in combination with vonoprazan as co-packaged dual therapy to treat H. pylori infection in adults.
- Associated Conditions
- Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections
Simplified Antibiotic Therapy for Sepsis in Young Infants
- Conditions
- Neonatal SepsisSepsisInfection
- Interventions
- First Posted Date
- 2009-12-08
- Last Posted Date
- 2015-06-29
- Lead Sponsor
- Aga Khan University
- Target Recruit Count
- 2543
- Registration Number
- NCT01027429
- Locations
- 🇵🇰
Ali Akber Shah Goth, Karachi, Sindh, Pakistan
Place of Antibiotics in the Postoperative Acute Lithiasic Cholecystitis
- Conditions
- Acute Lithiasic Cholecystitis Grade I or IISymptoms Lasting for Less Than 5 DaysRequired CholecystectomyPreoperative Amoxicillin Clavulanic Acid for at Most 5 Days
- Interventions
- Other: No medication
- First Posted Date
- 2009-11-18
- Last Posted Date
- 2016-04-28
- Lead Sponsor
- Centre Hospitalier Universitaire, Amiens
- Target Recruit Count
- 414
- Registration Number
- NCT01015417
- Locations
- 🇫🇷
Centre de Chirurgie Viscérale et de Transplantation Centre Hospitalier Régional Universitaire, Strasbourg, Alsace, France
🇫🇷Centre Hospitalier Haut-Lévêque, Bordeaux, Aquitaine, France
🇫🇷Service de Chirurgie Générale et Digestive. Centre Hospitalier Universitaire, Clermont-Ferrand, Auvergne, France
Effectiveness of Oral Antibiotics in the Treatment of Severe Acute Malnutrition
- Conditions
- KwashiorkorMarasmus
- Interventions
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2011-07-06
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 2700
- Registration Number
- NCT01000298
- Locations
- 🇲🇼
St. Louis Nutrition Project, Blantyre, Malawi
Cotrimoxazole Versus Amoxicillin in the Treatment of Community Acquired Pneumonia in Children Aged 2-59 Months
- Conditions
- Childhood Pneumonia
- Interventions
- First Posted Date
- 2009-07-07
- Last Posted Date
- 2009-07-07
- Lead Sponsor
- Makerere University
- Target Recruit Count
- 505
- Registration Number
- NCT00933049
- Locations
- 🇺🇬
Faculty of Medicine, Makerere University, Kampala, Uganda
Trial Assessing the Efficacy of a Short Course of Intravenous Antibiotic Followed by Oral Antibiotic in Uncomplicated Acute Diverticulitis
- First Posted Date
- 2009-06-10
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Consorci Sanitari de Terrassa
- Target Recruit Count
- 50
- Registration Number
- NCT00917592
- Locations
- 🇪🇸
Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain
Trial of Amoxicillin Compared With Placebo for Pneumonia in Children Aged 2-59 Months
- Conditions
- Acute Respiratory InfectionsPneumonia
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-02-26
- Last Posted Date
- 2009-02-26
- Lead Sponsor
- Pakistan Institute of Medical Sciences
- Target Recruit Count
- 900
- Registration Number
- NCT00851487
- Locations
- 🇵🇰
ARI Research Cell, Children Hospital, PIMS, Islamabad, Federal Capital, Pakistan
Evaluation of Inflammatory Symptoms Reduction With Amoxicillin + Ketoprofen in Acute Pharyngeal Tonsillitis in Pediatric Patients
- Conditions
- Pharyngotonsillitis
- Interventions
- First Posted Date
- 2008-12-01
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 106
- Registration Number
- NCT00799838
- Locations
- 🇧🇷
Sanofi-Aventis Administrative Office, Sao Paulo, Brazil
Bioequivalence Study of Amoxicillin Dispersible 600 mg Tablets Under Fasting Conditions
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2008-10-23
- Lead Sponsor
- Ranbaxy Laboratories Limited
- Target Recruit Count
- 26
- Registration Number
- NCT00778050
- Locations
- 🇺🇸
PRACS Institute Ltd., Fargo, North Dakota, United States
Bioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fasting Conditions
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2008-10-23
- Lead Sponsor
- Ranbaxy Laboratories Limited
- Target Recruit Count
- 40
- Registration Number
- NCT00778661
- Locations
- 🇺🇸
MDS Pharma Services, Phoenix, Arizona, United States
Bioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fed Conditions
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2008-10-23
- Lead Sponsor
- Ranbaxy Laboratories Limited
- Target Recruit Count
- 40
- Registration Number
- NCT00778284
- Locations
- 🇺🇸
MDS Pharma Services, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.